Sanofi and Johnson & Johnson's E. coli Vaccine Candidate Fails in Phase 3 Trial on February 14, 2025 E. coli disease Escherichia coli ExPEC9V Failure (biologic function) Invasive Johnson & Johnson Phase 3 Trial sanofi Vaccines +
Sanofi's E. coli Vaccine Fails Phase 3 Trial, Resulting in $250M Impairment Charge on February 13, 2025 charge amounts Clinical Trials Escherichia coli Failure (biologic function) Impaired Johnson & Johnson Phase 3 sanofi Vaccines +